Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Frontiers | Berberine as a Potential Agent for the Treatment of Colorectal Cancer
Lonsurf 20 Mg 8 19 Mg Tablets at Rs 89000/box in Udaipur | ID: 2851579876848
Lonsurf Tablets | Trifluridine and Tipiracil Colon Cancer - LetsMeds
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
FDA Approves Combination Drug to Treat Patients with Advanced Colorectal Cancer - NCI
Le fruquintinib prolonge durée de survie dans les cas de cancer colorectal métastatique réfractaire
NCCN® Guidelines for Metastatic Colon Cancer Treatment
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
Nanotechnologies for the treatment of colon cancer: From old drugs to new hope - ScienceDirect
FDA Broadens Lonsurf Use in Colorectal Cancer - MMIT
How to Take LONSURF® (trifluridine and tipiracil) tablets | Helpful Dosage Reminders
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice - ScienceDirect
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
Lonsurf (trifluridine/tipiracil) 20mg Tablet ^ Price in Pakistan - MedicalStore.com.pk
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? - The Lancet Oncology
Avastin and Lonsurf for Advanced Colorectal Cancer - NCI
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
NCCN® Guidelines for Metastatic Colon Cancer Treatment
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
Un anticancéreux de Servier obtient son AMM européenne | Le Quotidien du Pharmacien
